Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Retained Earnings data on record, last reported at -$159.1 million in Q1 2026.

  • On a quarterly basis, Retained Earnings fell 47.18% to -$159.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$159.1 million, a 47.18% decrease, with the full-year FY2025 number at $21802.0, up 100.02% from a year prior.
  • Retained Earnings reached -$159.1 million in Q1 2026 per IKT's latest filing, down from $21802.0 in the prior quarter.
  • Over the last five years, Retained Earnings for IKT hit a ceiling of $165822.0 in Q1 2023 and a floor of -$159.1 million in Q1 2026.
  • A 5-year average of -$43.3 million and a median of -$34.5 million in 2022 define the central range for Retained Earnings.
  • On a YoY basis, Retained Earnings climbed as much as 1326.57% in 2024 and fell as far as 10766418.24% in 2024.
  • Tracing IKT's Retained Earnings over 5 years: stood at -$47.9 million in 2022, then surged by 100.0% to $877.0 in 2023, then crashed by 10766418.24% to -$94.4 million in 2024, then skyrocketed by 100.02% to $21802.0 in 2025, then crashed by 729849.56% to -$159.1 million in 2026.
  • Business Quant data shows Retained Earnings for IKT at -$159.1 million in Q1 2026, $21802.0 in Q4 2025, and -$4189.0 in Q3 2025.